Trial reportAnnals of the rheumatic diseases2002
Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion.
Trial report in Annals of the rheumatic diseases, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 78 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase 3: Randomised Controlled Trial of Rituximab in Active Ulcerative Colitis
Rituximab in the Treatment of Patients With Bullous Pemphigoid
Who cites it
78 citing papers in PubMed.
- Ultra-low dose of rituximab in rheumatoid arthritis: study protocol for a randomised controlled trial.Trials · 2017Trial
- Trial
- Reactivation of latent viruses in individuals receiving rituximab for new onset type 1 diabetes.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2013Trial
- Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system.Annals of the rheumatic diseases · 2007Trial
- Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial.American journal of respiratory and critical care medicine · 2006Trial
- A phase II study of Rituximab in rheumatoid arthritis patients with recurrent disease following haematopoietic stem cell transplantation.Bone marrow transplantation · 2004Trial
- Anti-cancer Drugs in Endometriosis Management: Mechanisms and Therapeutic Potential.Current pharmaceutical design · 2026Review
- CAR-T Cell Therapy: Managing Side Effects and Overcoming Challenges.Advanced biomedical research · 2025Review
- Article
- Autoimmunity: the neoantigen hypothesis.Frontiers in immunology · 2024Article
- Article
- Advancing Biologic Therapy for Refractory Autoimmune Hepatitis.Digestive diseases and sciences · 2022Review
- Paradoxical Duel Role of Collagen in Rheumatoid Arthritis: Cause of Inflammation and Treatment.Bioengineering (Basel, Switzerland) · 2022Review
- Disparity in peripheral and renal B-cell depletion with rituximab in systemic lupus erythematosus: an opportunity for obinutuzumab?Rheumatology (Oxford, England) · 2022Article
- Long-term persistence of rituximab in patients with rheumatoid arthritis: an evaluation of the UCL cohort from 1998 to 2020.Rheumatology (Oxford, England) · 2022Article
- The preventive Effectiveness of Rituximab in Pediatric Autoimmune and Inflammatory CNS Diseases Relapse: an Iranian Experience.Iranian journal of child neurology · 2022Article
- Article
- (Ultra-)low dosing of rituximab in rheumatoid arthritis: chances and challenges.Rheumatology advances in practice · 2021Article
- Exploration and Evaluation of Therapeutic Efficacy of Drug-Free Macromolecular Therapeutics in Collagen-Induced Rheumatoid Arthritis Mouse Model.Macromolecular bioscience · 2020Article
- Added value recyclability of glass fiber waste as photo-oxidation catalyst for toxic cytostatic micropollutants.Scientific reports · 2020Article
18 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo obtain evidence for dose response and to extend evidence of safety and efficacy for B lymphocyte depletion in rheumatoid arthritis.
methodsTwenty two patients with rheumatoid arthritis received a total of 29 treatments with five different combinations of rituximab (RTX), cyclophosphamide (CP), and/or high dose prednisolone (PR) on an open basis as follows; cohort I: RTX 1400 mg/m(2), CP 750x2+PR; cohort II: RTX 300-700 mg/m(2), -CP+/-PR); cohort III: RTX 600-700 mg/m(2), CP 750x2+PR; cohort IV: RTX 1200 mg/m(2), CP 750x2-PR; cohort V: RTX 500 mg/m(2), CP 750x2+PR. American College of Rheumatology (ACR) criteria of improvement at six months were chosen as the primary outcome measure. Disease activity scores and total duration of improvement and of B cytopenia were also recorded.
resultsNo major adverse events attributable to treatment were seen. ACR grades of improvement at six months were as follows: cohort I: ACR70x3, ACR50x2; cohort II: ACR20x1, ACR0x3; cohort III: ACR70x6, ACR50x2, ACR20x2; cohort IV: ACR70x2, ACR50x2, ACR20x1, ACR0x1; cohort V: ACR0x4.
conclusionsB lymphocyte depletion in rheumatoid arthritis has so far proved to be safe and associated with major improvement with protocols including RTX 600 mg/m(2) or more and CP, but not with more limited protocols. These observations provide an initial basis for the design of formal trials of B cell depletion and other B cell directed treatments, including a phase II controlled trial now in progress.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.